Trial watch

References

• Tato CM, Cua DJ. SnapShot: Cytokines I. Cell 2008; 132:324. e1
   Google Scholar
• Tato CM, Cua DJ. SnapShot: cytokines II. Cell 2008; 132:500; PMID: 18267079
   PubMedGoogle Scholar
• Tato CM, Cua DJ. SnapShot: cytokines III. Cell 2008; 132:900; PMID: 18329374
   PubMed Web of Science ®Google Scholar
• Tato CM, Cua DJ. SnapShot: Cytokines IV. Cell 2008; 132:e1 - 2; PMID: 18358817
   PubMedGoogle Scholar
• Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2013; 2:e24850; http://dx.doi.org/10.4161/onci.24850; PMID: 24073369
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012; 1:493 - 506; http://dx.doi.org/10.4161/onci.20459; PMID: 22754768
   PubMed Web of Science ®Google Scholar
• Papatriantafyllou M. Cytokines: true to their family name. Nat Rev Immunol 2013; 13:544 - 5; http://dx.doi.org/10.1038/nri3496; PMID: 23827957
   PubMed Web of Science ®Google Scholar
• Borish LC, Steinke JW. 2. Cytokines and chemokines. J Allergy Clin Immunol 2003; 111:Suppl S460 - 75; http://dx.doi.org/10.1067/mai.2003.108; PMID: 12592293
   PubMedGoogle Scholar
• Steinke JW, Borish L. 3. Cytokines and chemokines. J Allergy Clin Immunol 2006; 117:Suppl Mini-Primer S441 - 5; http://dx.doi.org/10.1016/j.jaci.2005.07.001; PMID: 16455343
   PubMed Web of Science ®Google Scholar
• Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer 2010; 10:425 - 34; http://dx.doi.org/10.1038/nrc2843; PMID: 20495576
   PubMed Web of Science ®Google Scholar
• Neufeld G, Kessler O. Pro-angiogenic cytokines and their role in tumor angiogenesis. Cancer Metastasis Rev 2006; 25:373 - 85; http://dx.doi.org/10.1007/s10555-006-9011-5; PMID: 17006765
   PubMed Web of Science ®Google Scholar
• Benelli R, Lorusso G, Albini A, Noonan DM. Cytokines and chemokines as regulators of angiogenesis in health and disease. Curr Pharm Des 2006; 12:3101 - 15; http://dx.doi.org/10.2174/138161206777947461; PMID: 16918437
   PubMed Web of Science ®Google Scholar
• Ohlsson K, Björk P, Bergenfeldt M, Hageman R, Thompson RC. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348:550 - 2; http://dx.doi.org/10.1038/348550a0; PMID: 2147233
   PubMed Web of Science ®Google Scholar
• Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662 - 4; http://dx.doi.org/10.1038/330662a0; PMID: 3317066
   PubMed Web of Science ®Google Scholar
• Andrews DM, Chow MT, Ma Y, Cotterell CL, Watt SV, Anthony DA, Akira S, Iwakura Y, Trapani JA, Zitvogel L, et al. Homeostatic defects in interleukin 18-deficient mice contribute to protection against the lethal effects of endotoxin. Immunol Cell Biol 2011; 89:739 - 46; http://dx.doi.org/10.1038/icb.2010.168; PMID: 21263463
   PubMed Web of Science ®Google Scholar
• Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 2005; 6:1191 - 7; http://dx.doi.org/10.1038/ni1276; PMID: 16369558
   PubMed Web of Science ®Google Scholar
• Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol 2013; 59:583 - 94; http://dx.doi.org/10.1016/j.jhep.2013.03.033; PMID: 23567086
   PubMed Web of Science ®Google Scholar
• Senovilla L, Galluzzi L, Zitvogel L, Kroemer G. Immunosurveillance as a regulator of tissue homeostasis. Trends Immunol 2013; 34:471 - 81; http://dx.doi.org/10.1016/j.it.2013.06.005; PMID: 23891238
   PubMed Web of Science ®Google Scholar
• Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004; 4:11 - 22; http://dx.doi.org/10.1038/nrc1252; PMID: 14708024
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860 - 7; http://dx.doi.org/10.1038/nature01322; PMID: 12490959
   PubMed Web of Science ®Google Scholar
• Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet?. Science 2013; 339:286 - 91; http://dx.doi.org/10.1126/science.1232227; PMID: 23329041
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013; 2:e25771; http://dx.doi.org/10.4161/onci.25771; PMID: 24286020
   PubMed Web of Science ®Google Scholar
• Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: DNA vaccines for cancer therapy. Oncoimmunology 2014; 3:e28185; http://dx.doi.org/10.4161/onci.28185; PMID: 24800178
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology 2013; 2:e26621; http://dx.doi.org/10.4161/onci.26621; PMID: 24498550
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2:e25238; http://dx.doi.org/10.4161/onci.25238; PMID: 24083080
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, Prada N, Adjemian S, Catani JP, Freudenberg M, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ 2014; 21:69 - 78; http://dx.doi.org/10.1038/cdd.2013.72; PMID: 23811849
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; http://dx.doi.org/10.4161/onci.27297; PMID: 24701370
   PubMed Web of Science ®Google Scholar
• Arellano M, Lonial S. Clinical uses of GM-CSF, a critical appraisal and update. Biologics 2008; 2:13 - 27; http://dx.doi.org/10.2147/BTT.S1355; PMID: 19707424
   PubMedGoogle Scholar
• Khoury HJ, Loberiza FR Jr., Ringdén O, Barrett AJ, Bolwell BJ, Cahn JY, Champlin RE, Gale RP, Hale GA, Urbano-Ispizua A, et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 2006; 107:1712 - 6; http://dx.doi.org/10.1182/blood-2005-07-2661; PMID: 16239431
   PubMed Web of Science ®Google Scholar
• Sebban C, Lefranc A, Perrier L, Moreau P, Espinouse D, Schmidt A, Kammoun L, Ghesquieres H, Ferlay C, Bay JO, et al. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). Eur J Cancer 2012; 48:713 - 20; http://dx.doi.org/10.1016/j.ejca.2011.12.016; PMID: 22248711
   PubMed Web of Science ®Google Scholar
• Hosing C. Hematopoietic stem cell mobilization with G-CSF. Methods Mol Biol 2012; 904:37 - 47; PMID: 22890920
   PubMedGoogle Scholar
• Demirer T, Ayli M, Ozcan M, Gunel N, Haznedar R, Dagli M, Fen T, Genc Y, Dincer S, Arslan O, et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002; 116:468 - 74; http://dx.doi.org/10.1046/j.1365-2141.2002.03264.x; PMID: 11841454
   PubMed Web of Science ®Google Scholar
• Naeim A, Henk HJ, Becker L, Chia V, Badre S, Li X, Deeter R. Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF). BMC Cancer 2013; 13:11; http://dx.doi.org/10.1186/1471-2407-13-11; PMID: 23298389
   PubMed Web of Science ®Google Scholar
• Chan KK, Siu E, Krahn MD, Imrie K, Alibhai SM. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. J Clin Oncol 2012; 30:1064 - 71; http://dx.doi.org/10.1200/JCO.2011.36.8647; PMID: 22393098
   PubMed Web of Science ®Google Scholar
• Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Vekemans MC, Biemond B, Sonneveld P, Passweg J, Verdonck L, et al, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), German AML Study Group (AMLSG), Swiss Collaborative Group for Clinical Cancer Research (SAKK). Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood 2012; 119:5367 - 73; http://dx.doi.org/10.1182/blood-2011-11-389841; PMID: 22422824
   PubMed Web of Science ®Google Scholar
• Deroose JP, Eggermont AM, van Geel AN, Burger JW, den Bakker MA, de Wilt JH, Verhoef C. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J Clin Oncol 2011; 29:4036 - 44; http://dx.doi.org/10.1200/JCO.2011.35.6618; PMID: 21931039
   PubMed Web of Science ®Google Scholar
• Deroose JP, Eggermont AM, van Geel AN, de Wilt JH, Burger JW, Verhoef C. 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. Ann Surg Oncol 2012; 19:627 - 35; http://dx.doi.org/10.1245/s10434-011-2030-7; PMID: 21879272
   PubMed Web of Science ®Google Scholar
• Deroose JP, Grünhagen DJ, van Geel AN, de Wilt JH, Eggermont AM, Verhoef C. Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases. Br J Surg 2011; 98:1573 - 80; http://dx.doi.org/10.1002/bjs.7621; PMID: 21739427
   PubMed Web of Science ®Google Scholar
• Eggermont AM. The success of TNF alpha in isolated limb perfusion for irresectable extremity soft tissue sarcomas, melanoma and carcinomas: observations in patients and preclinical perfusion models. Gan To Kagaku Ryoho 1996; 23:1357 - 70; PMID: 8854755
   PubMedGoogle Scholar
• Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Liénard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996; 224:756 - 64, discussion 764-5; http://dx.doi.org/10.1097/00000658-199612000-00011; PMID: 8968230
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Schraffordt Koops H, Klausner JM, Schlag PM, Kroon BB, Ben-Ari G, Lejeune FJ. Isolated limb perfusion with high-dose tumor necrosis factor-alpha for locally advanced extremity soft tissue sarcomas. Cancer Treat Res 1997; 91:189 - 203; http://dx.doi.org/10.1007/978-1-4615-6121-7_13; PMID: 9286497
   PubMedGoogle Scholar
• Eggermont AM, Schraffordt Koops H, Liénard D, Kroon BB, van Geel AN, Hoekstra HJ, Lejeune FJ. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 1996; 14:2653 - 65; PMID: 8874324
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, Punt CJ, Salès F, Dummer R, Robert C, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol 2012; 30:3810 - 8; http://dx.doi.org/10.1200/JCO.2011.41.3799; PMID: 23008300
   PubMed Web of Science ®Google Scholar
• Grünhagen DJ, Brunstein F, ten Hagen TL, van Geel AN, de Wilt JH, Eggermont AM. TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat Res 2004; 120:65 - 79; http://dx.doi.org/10.1007/1-4020-7856-0_4; PMID: 15217218
   PubMedGoogle Scholar
• Trabulsi NH, Patakfalvi L, Nassif MO, Turcotte RE, Nichols A, Meguerditchian AN. Hyperthermic isolated limb perfusion for extremity soft tissue sarcomas: systematic review of clinical efficacy and quality assessment of reported trials. J Surg Oncol 2012; 106:921 - 8; http://dx.doi.org/10.1002/jso.23200; PMID: 22806575
   PubMed Web of Science ®Google Scholar
• Grünhagen DJ, de Wilt JH, ten Hagen TL, Eggermont AM. Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nat Clin Pract Oncol 2006; 3:94 - 103; http://dx.doi.org/10.1038/ncponc0426; PMID: 16462850
   PubMedGoogle Scholar
• Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105 - 16; PMID: 10561265
   PubMed Web of Science ®Google Scholar
• Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996; 14:2410 - 1; PMID: 8708739
   PubMed Web of Science ®Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688 - 96; PMID: 7884429
   PubMed Web of Science ®Google Scholar
• Hauschild A. Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?. Curr Oncol 2009; 16:3 - 6; http://dx.doi.org/10.3747/co.v16i3.447; PMID: 19526078
   PubMed Web of Science ®Google Scholar
• Anger B, Porzsolt F, Leichtle R, Heinze B, Bartram C, Heimpel H. A phase I/II study of recombinant interferon alpha 2a and hydroxyurea for chronic myelocytic leukemia. Blut 1989; 58:275 - 8; http://dx.doi.org/10.1007/BF00320165; PMID: 2736308
   PubMedGoogle Scholar
• Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai WY, McBride R, Bennett CL, Grann VR. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99:196 - 205; http://dx.doi.org/10.1093/jnci/djk028; PMID: 17284714
   PubMed Web of Science ®Google Scholar
• Di Cosimo S, Ferretti G, Papaldo P, Carlini P, Fabi A, Ruggeri EM, Alimonti A, Nardoni C, Cognetti F. Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?. Ann Oncol 2005; 16:1209 - 10; http://dx.doi.org/10.1093/annonc/mdi201; PMID: 15857847
   PubMed Web of Science ®Google Scholar
• Relling MV, Boyett JM, Blanco JG, Raimondi S, Behm FG, Sandlund JT, Rivera GK, Kun LE, Evans WE, Pui CH. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003; 101:3862 - 7; http://dx.doi.org/10.1182/blood-2002-08-2405; PMID: 12531808
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Obrist F, Eggermont A, Fridman WH, Galon J, et al. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. OncoImmunology 2013; 2:e24238; http://dx.doi.org/10.4161/onci.24238
   Google Scholar
• Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215 - 33; http://dx.doi.org/10.1038/nrd3626; PMID: 22301798
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74 - 88; http://dx.doi.org/10.1016/j.immuni.2013.06.014; PMID: 23890065
   PubMed Web of Science ®Google Scholar
• Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342:971 - 6; http://dx.doi.org/10.1126/science.1240537; PMID: 24264990
   PubMed Web of Science ®Google Scholar
• Becker JC, Schrama D. The dark side of cyclophosphamide: cyclophosphamide-mediated ablation of regulatory T cells. J Invest Dermatol 2013; 133:1462 - 5; http://dx.doi.org/10.1038/jid.2013.67; PMID: 23673502
   PubMed Web of Science ®Google Scholar
• Connor JP, Cristea MC, Lewis NL, Lewis LD, Komarnitsky PB, Mattiacci MR, Felder M, Stewart S, Harter J, Henslee-Downey J, et al. A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. BMC Cancer 2013; 13:20; http://dx.doi.org/10.1186/1471-2407-13-20; PMID: 23320927
   PubMed Web of Science ®Google Scholar
• Dutcher JP, Neuberg D, Atkins MB, Tester WJ, Wadler S, Stewart JA, Chachoua A, Schuchter LM. Report of a Phase I Evaluation of Dose and Schedule of Interleukin-1 Alpha and Cyclophosphamide in Patients with Advanced Tumors: An Eastern Cooperative Oncology Group Study (PX990) and Review of IL-1-Based Studies of Hematopoietic Reconstitution. J Interferon Cytokine Res 2014; 34:376 - 84; http://dx.doi.org/10.1089/jir.2013.0010; PMID: 24433038
   PubMed Web of Science ®Google Scholar
• Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 2006; 17:1733 - 42; http://dx.doi.org/10.1093/annonc/mdl105; PMID: 16801334
   PubMed Web of Science ®Google Scholar
• Reubi JC, Schonbrunn A. Illuminating somatostatin analog action at neuroendocrine tumor receptors. Trends Pharmacol Sci 2013; 34:676 - 88; http://dx.doi.org/10.1016/j.tips.2013.10.001; PMID: 24183675
   PubMed Web of Science ®Google Scholar
• Vitale G, Lupoli G, Guarrasi R, Colao A, Dicitore A, Gaudenzi G, Misso G, Castellano M, Addeo R, Facchini G, et al. Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2013; 98:E1567 - 74; http://dx.doi.org/10.1210/jc.2013-1443; PMID: 23884781
   PubMedGoogle Scholar
• Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:894 - 907; http://dx.doi.org/10.4161/onci.20931; PMID: 23162757
   PubMed Web of Science ®Google Scholar
• Cutando A, López-Valverde A, Arias-Santiago S, DE Vicente J, DE Diego RG. Role of melatonin in cancer treatment. Anticancer Res 2012; 32:2747 - 53; PMID: 22753734
   PubMed Web of Science ®Google Scholar
• Vishwas DK, Mukherjee A, Haldar C. Melatonin improves humoral and cell-mediated immune responses of male golden hamster following stress induced by dexamethasone. J Neuroimmunol 2013; 259:17 - 25; http://dx.doi.org/10.1016/j.jneuroim.2013.03.002; PMID: 23582490
   PubMed Web of Science ®Google Scholar
• Srinivasan V, Pandi-Perumal SR, Brzezinski A, Bhatnagar KP, Cardinali DP. Melatonin, immune function and cancer. Recent Pat Endocr Metab Immune Drug Discov 2011; 5:109 - 23; http://dx.doi.org/10.2174/187221411799015408; PMID: 22074586
   PubMedGoogle Scholar
• Tomov B, Popov D, Tomova R, Vladov N, Den Otter W, Krastev Z. Therapeutic response of untreatable hepatocellular carcinoma after application of the immune modulators IL-2, BCG and melatonin. Anticancer Res 2013; 33:4531 - 5; PMID: 24123026
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; http://dx.doi.org/10.4161/onci.22789; PMID: 23482847
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27048; http://dx.doi.org/10.4161/onci.27048; PMID: 24605265
   PubMed Web of Science ®Google Scholar
• Akhtar S, Maghfoor I. Rituximab plus CHOP for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1830 - 1, author reply 1830-1; http://dx.doi.org/10.1056/NEJM200206063462317; PMID: 12050349
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235 - 42; http://dx.doi.org/10.1056/NEJMoa011795; PMID: 11807147
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Kline J, Struemper H, Koch KM, Bauman JW, Gardner OS, Murray SC, Germaschewski F, Weisenbach J, Jonak Z, et al. A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma. J Immunother 2013; 36:331 - 41; http://dx.doi.org/10.1097/CJI.0b013e31829d7e2e; PMID: 23799412
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28 - 37; http://dx.doi.org/10.4161/onci.1.1.17938; PMID: 22720209
   PubMed Web of Science ®Google Scholar
• Hale G, Bright S, Chumbley G, Hoang T, Metcalf D, Munro AJ, Waldmann H. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood 1983; 62:873 - 82; PMID: 6349718
   PubMed Web of Science ®Google Scholar
• Gorin NC, Isnard F, Garderet L, Ikhlef S, Corm S, Quesnel B, Legrand O, Cachanado M, Rousseau A, Laporte JP. Administration of alemtuzumab and G-CSF to adults with relapsed or refractory acute lymphoblastic leukemia: results of a phase II study. Eur J Haematol 2013; 91:315 - 21; PMID: 23738686
   PubMed Web of Science ®Google Scholar
• Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood 1989; 73:1936 - 41; PMID: 2653466
   PubMed Web of Science ®Google Scholar
• Heiner JP, Miraldi F, Kallick S, Makley J, Neely J, Smith-Mensah WH, Cheung NK. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res 1987; 47:5377 - 81; PMID: 3115567
   PubMed Web of Science ®Google Scholar
• Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, Spitzer T, Strandjord SE, Coccia PF, Berger NA. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987; 5:1430 - 40; PMID: 3625258
   PubMed Web of Science ®Google Scholar
• Cheung IY, Hsu K, Cheung NK. Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2012; 30:426 - 32; http://dx.doi.org/10.1200/JCO.2011.37.6236; PMID: 22203761
   PubMed Web of Science ®Google Scholar
• Cheung NK, Cheung IY, Kramer K, Modak S, Kuk D, Pandit-Taskar N, Chamberlain E, Ostrovnaya I, Kushner BH. Key role for myeloid cells: Phase II results of anti-GD2 antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. Int J Cancer 2014; Forthcoming http://dx.doi.org/10.1002/ijc.28851; PMID: 24644014
   PubMed Web of Science ®Google Scholar
• Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. Oncoimmunology 2012; 1:477 - 86; http://dx.doi.org/10.4161/onci.19864; PMID: 22754766
   PubMed Web of Science ®Google Scholar
• Zarogoulidis K, Ziogas E, Boutsikou E, Zarogoulidis P, Darwiche K, Kontakiotis T, Tsakiridis K, Porpodis K, Latsios D, Chatzizisi O, et al. Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study. Drug Des Devel Ther 2013; 7:611 - 7; http://dx.doi.org/10.2147/DDDT.S43184; PMID: 23901264
   PubMed Web of Science ®Google Scholar
• Coker SA, Dandamudi UB, Beelen AP, Crosby NA, Fisher JL, Obrocea M, Ernstoff MS, Lewis LD. A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours. J Chemother 2013; 25:362 - 8; http://dx.doi.org/10.1179/1973947813Y.0000000102; PMID: 24093213
   PubMed Web of Science ®Google Scholar
• Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, Tsukamoto T, Azuma H, Matsubara A, Nishimura K, et al, Japan Immunotherapy SNPs-Study Group for Kidney Cancer. STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma. Eur Urol 2013; 63:745 - 52; http://dx.doi.org/10.1016/j.eururo.2012.09.052; PMID: 23063454
   PubMed Web of Science ®Google Scholar
• Ito N, Eto M, Nakamura E, Takahashi A, Tsukamoto T, Toma H, Nakazawa H, Hirao Y, Uemura H, Kagawa S, et al. STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol 2007; 25:2785 - 91; http://dx.doi.org/10.1200/JCO.2006.09.8897; PMID: 17602083
   PubMed Web of Science ®Google Scholar
• Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6:734 - 45; http://dx.doi.org/10.1038/nrd2380; PMID: 17690708
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115 - 24; http://dx.doi.org/10.1056/NEJMoa065044; PMID: 17215529
   PubMed Web of Science ®Google Scholar
• Nicholaou T, Wong R, Davis ID. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet 2007; 369:1923 - 4; http://dx.doi.org/10.1016/S0140-6736(07)60903-9; PMID: 17560435
   PubMed Web of Science ®Google Scholar
• Harmon CS, DePrimo SE, Figlin RA, Hudes GR, Hutson TE, Michaelson MD, Négrier S, Kim ST, Huang X, Williams JA, et al. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2014; 73:151 - 61; http://dx.doi.org/10.1007/s00280-013-2333-4; PMID: 24220935
   PubMed Web of Science ®Google Scholar
• Guermonprez P, Helft J, Claser C, Deroubaix S, Karanje H, Gazumyan A, Darasse-Jèze G, Telerman SB, Breton G, Schreiber HA, et al. Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nat Med 2013; 19:730 - 8; http://dx.doi.org/10.1038/nm.3197; PMID: 23685841
   PubMed Web of Science ®Google Scholar
• Sim GC, Martin-Orozco N, Jin L, Yang Y, Wu S, Washington E, Sanders D, Lacey C, Wang Y, Vence L, et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Invest 2014; 124:99 - 110; http://dx.doi.org/10.1172/JCI46266; PMID: 24292706
   PubMed Web of Science ®Google Scholar
• Mortha A, Chudnovskiy A, Hashimoto D, Bogunovic M, Spencer SP, Belkaid Y, Merad M. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science 2014; 343:1249288; http://dx.doi.org/10.1126/science.1249288; PMID: 24625929
   PubMed Web of Science ®Google Scholar
• West EE, Jin HT, Rasheed AU, Penaloza-Macmaster P, Ha SJ, Tan WG, Youngblood B, Freeman GJ, Smith KA, Ahmed R. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest 2013; 123:2604 - 15; http://dx.doi.org/10.1172/JCI67008; PMID: 23676462
   PubMed Web of Science ®Google Scholar
• Omori R, Eguchi J, Hiroishi K, Ishii S, Hiraide A, Sakaki M, Doi H, Kajiwara A, Ito T, Kogo M, et al. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors. Cancer Gene Ther 2012; 19:637 - 43; http://dx.doi.org/10.1038/cgt.2012.42; PMID: 22790963
   PubMed Web of Science ®Google Scholar
• Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 2012; 18:2039 - 47; http://dx.doi.org/10.1158/1078-0432.CCR-11-1823; PMID: 22271879
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; http://dx.doi.org/10.4161/onci.24238; PMID: 23762803
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr., Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673 - 84; http://dx.doi.org/10.1056/NEJMoa052122; PMID: 16236738
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al, Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659 - 72; http://dx.doi.org/10.1056/NEJMoa052306; PMID: 16236737
   PubMed Web of Science ®Google Scholar
• Mavilio D, Galluzzi L, Lugli E. Novel multifunctional antibody approved for the treatment of breast cancer. Oncoimmunology 2013; 2:e24567; http://dx.doi.org/10.4161/onci.24567; PMID: 23802090
   PubMedGoogle Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al, ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687 - 97; http://dx.doi.org/10.1016/S0140-6736(10)61121-X; PMID: 20728210
   PubMed Web of Science ®Google Scholar
• Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375:377 - 84; http://dx.doi.org/10.1016/S0140-6736(09)61964-4; PMID: 20113825
   PubMed Web of Science ®Google Scholar
• Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, et al, HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29 - 36; http://dx.doi.org/10.1016/S0140-6736(07)60028-2; PMID: 17208639
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Mavilio D, Lugli E. Inhibiting the inhibitors: Checkpoints blockade in solid tumors. Oncoimmunology 2013; 2:e26535; http://dx.doi.org/10.4161/onci.26535; PMID: 24244910
   PubMedGoogle Scholar
• Robert C, Thomas L, Bondarenko I, O’Day S, M D JW, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517 - 26; http://dx.doi.org/10.1056/NEJMoa1104621; PMID: 21639810
   PubMed Web of Science ®Google Scholar
• Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 2013; 31:71 - 5; http://dx.doi.org/10.1038/nbt.2459; PMID: 23242161
   PubMed Web of Science ®Google Scholar
• Schroten C, Kraaij R, Veldhoven JL, Berrevoets CA, den Bakker MA, Ma Q, Sadelain M, Bangma CH, Willemsen RA, Debets R. T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy. J Immunol Methods 2010; 359:11 - 20; http://dx.doi.org/10.1016/j.jim.2010.04.006; PMID: 20460126
   PubMed Web of Science ®Google Scholar
• Modak S, Kushner BH, Kramer K, Vickers A, Cheung IY, Cheung NK. Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma. Oncoimmunology 2013; 2:e23402; http://dx.doi.org/10.4161/onci.23402; PMID: 23802080
   PubMed Web of Science ®Google Scholar
• Govindan SV, Goldenberg DM. Designing immunoconjugates for cancer therapy. Expert Opin Biol Ther 2012; 12:873 - 90; http://dx.doi.org/10.1517/14712598.2012.685153; PMID: 22679911
   PubMed Web of Science ®Google Scholar
• Albertini MR, Hank JA, Gadbaw B, Kostlevy J, Haldeman J, Schalch H, Gan J, Kim K, Eickhoff J, Gillies SD, et al. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Cancer Immunol Immunother 2012; 61:2261 - 71; http://dx.doi.org/10.1007/s00262-012-1286-5; PMID: 22678096
   PubMed Web of Science ®Google Scholar
• Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012; 17:583 - 90; http://dx.doi.org/10.1016/j.drudis.2012.01.007; PMID: 22289353
   PubMed Web of Science ®Google Scholar
• Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006; 12:3200 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-05-2804; PMID: 16707621
   PubMed Web of Science ®Google Scholar
• Gutbrodt KL, Schliemann C, Giovannoni L, Frey K, Pabst T, Klapper W, Berdel WE, Neri D. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med 2013; 5:ra118; http://dx.doi.org/10.1126/scitranslmed.3006221; PMID: 24005158
   PubMed Web of Science ®Google Scholar
• Spitaleri G, Berardi R, Pierantoni C, De Pas T, Noberasco C, Libbra C, González-Iglesias R, Giovannoni L, Tasciotti A, Neri D, et al. Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. J Cancer Res Clin Oncol 2013; 139:447 - 55; http://dx.doi.org/10.1007/s00432-012-1327-7; PMID: 23160853
   PubMed Web of Science ®Google Scholar
• Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, et al. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010; 46:2926 - 35; http://dx.doi.org/10.1016/j.ejca.2010.07.033; PMID: 20797845
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology 2013; 2:e25595; http://dx.doi.org/10.4161/onci.25595; PMID: 24319634
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
   PubMed Web of Science ®Google Scholar
• PD-1 inhibitors raise survival in NSCLC. Cancer Discov 2014; 4:6.
   Google Scholar
• Weintraub K. Drug development: Releasing the brakes. Nature 2013; 504:S6 - 8; http://dx.doi.org/10.1038/504S6a; PMID: 24352363
   PubMed Web of Science ®Google Scholar
• Dranoff G. Immunotherapy at large: Balancing tumor immunity and inflammatory pathology. Nat Med 2013; 19:1100 - 1; http://dx.doi.org/10.1038/nm.3335; PMID: 24013749
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134 - 44; http://dx.doi.org/10.1056/NEJMoa1305133; PMID: 23724846
   PubMed Web of Science ®Google Scholar
• Chen LL, Gouw L, Sabripour M, Hwu WJ, Benjamin RS. Combining targeted therapy with immunotherapy (interferon-α): Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies. Oncoimmunology 2012; 1:773 - 6; http://dx.doi.org/10.4161/onci.19729; PMID: 22934279
   PubMed Web of Science ®Google Scholar
• Yang Y, Lizée G, Hwu P. Strong emerging rationale for combining oncogene-targeted agents with immunotherapy. Oncoimmunology 2013; 2:e22730; http://dx.doi.org/10.4161/onci.22730; PMID: 23524978
   PubMed Web of Science ®Google Scholar
• Feldhahn N, Arutyunyan A, Stoddart S, Zhang B, Schmidhuber S, Yi SJ, Kim YM, Groffen J, Heisterkamp N. Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia. Oncoimmunology 2012; 1:618 - 29; http://dx.doi.org/10.4161/onci.20249; PMID: 22934254
   PubMed Web of Science ®Google Scholar
• Kim DK, Lee TV, Castilleja A, Anderson BW, Peoples GE, Kudelka AP, Murray JL, Sittisomwong T, Wharton JT, Kim JW, et al. Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients. Anticancer Res 1999; 19:4B 2907 - 16; PMID: 10652572
   PubMed Web of Science ®Google Scholar
• Peoples GE, Anderson BW, Lee TV, Murray JL, Kudelka AP, Wharton JT, Ioannides CG. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers. Clin Cancer Res 1999; 5:4214 - 23; PMID: 10632363
   PubMed Web of Science ®Google Scholar
• Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011; 29:330 - 6; http://dx.doi.org/10.1200/JCO.2010.30.7744; PMID: 21149657
   PubMed Web of Science ®Google Scholar
• Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, Bejjani GK, Hamilton RL, Torres-Trejo A, Kalinski P, Cai Q, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 2007; 5:67; http://dx.doi.org/10.1186/1479-5876-5-67; PMID: 18093335
   PubMed Web of Science ®Google Scholar
• Holcmann M, Drobits B, Sibilia M. How imiquimod licenses plasmacytoid dendritic cells to kill tumors. Oncoimmunology 2012; 1:1661 - 3; http://dx.doi.org/10.4161/onci.22033; PMID: 23264929
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699 - 716; http://dx.doi.org/10.4161/onci.20696; PMID: 22934262
   PubMed Web of Science ®Google Scholar
• Zauderer MG, Krug LM. Novel therapies in phase II and III trials for malignant pleural mesothelioma. J Natl Compr Canc Netw 2012; 10:42 - 7; PMID: 22223868
   PubMed Web of Science ®Google Scholar
• Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, Korontsvit T, Zakhaleva V, Wolchok J, Yuan J, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 2010; 59:1467 - 79; http://dx.doi.org/10.1007/s00262-010-0871-8; PMID: 20532500
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Leng S, Moschos SJ, Yin Y, Sander C, Lin Y, Gooding WE, Kirkwood JM. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother 2012; 35:359 - 66; http://dx.doi.org/10.1097/CJI.0b013e31825481fe; PMID: 22495394
   PubMed Web of Science ®Google Scholar
• Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, Schreibelt G, Mus R, De Wilt JH, Haanen JB, et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013; 73:19 - 29; http://dx.doi.org/10.1158/0008-5472.CAN-12-1127; PMID: 23087058
   PubMed Web of Science ®Google Scholar
• Aarntzen EH, Bol K, Schreibelt G, Jacobs JF, Lesterhuis WJ, Van Rossum MM, Adema GJ, Figdor CG, Punt CJ, De Vries IJ. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res 2012; 72:6102 - 10; http://dx.doi.org/10.1158/0008-5472.CAN-12-2479; PMID: 23010076
   PubMed Web of Science ®Google Scholar
• Su S, Zhou H, Xue M, Liu JY, Ding L, Cao M, Zhou ZX, Hu HM, Wang LX. Anti-tumor efficacy of a hepatocellular carcinoma vaccine based on dendritic cells combined with tumor-derived autophagosomes in murine models. Asian Pac J Cancer Prev 2013; 14:3109 - 16; http://dx.doi.org/10.7314/APJCP.2013.14.5.3109; PMID: 23803088
   PubMed Web of Science ®Google Scholar
• Li Y, Wang LX, Pang P, Cui Z, Aung S, Haley D, Fox BA, Urba WJ, Hu HM. Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res 2011; 17:7047 - 57; http://dx.doi.org/10.1158/1078-0432.CCR-11-0951; PMID: 22068657
   PubMed Web of Science ®Google Scholar
• Twitty CG, Jensen SM, Hu HM, Fox BA. Tumor-derived autophagosome vaccine: induction of cross-protective immune responses against short-lived proteins through a p62-dependent mechanism. Clin Cancer Res 2011; 17:6467 - 81; http://dx.doi.org/10.1158/1078-0432.CCR-11-0812; PMID: 21810919
   PubMed Web of Science ®Google Scholar
• Muhsin M, Graham J, Kirkpatrick P. Bevacizumab. Nat Rev Drug Discov 2004; 3:995 - 6; http://dx.doi.org/10.1038/nrd1601; PMID: 15645606
   PubMed Web of Science ®Google Scholar
• Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3:391 - 400; http://dx.doi.org/10.1038/nrd1381; PMID: 15136787
   PubMed Web of Science ®Google Scholar
• Lim SN, Kuhn S, Hyde E, Ronchese F. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy. J Immunother 2012; 35:670 - 9; http://dx.doi.org/10.1097/CJI.0b013e318270e135; PMID: 23090076
   PubMed Web of Science ®Google Scholar
• Hennies CM, Reboulet RA, Garcia Z, Nierkens S, Wolkers MC, Janssen EM. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo. Clin Exp Immunol 2011; 163:381 - 91; http://dx.doi.org/10.1111/j.1365-2249.2010.04305.x; PMID: 21235535
   PubMed Web of Science ®Google Scholar
• Curran MA, Allison JP. Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res 2009; 69:7747 - 55; http://dx.doi.org/10.1158/0008-5472.CAN-08-3289; PMID: 19738077
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306 - 15; http://dx.doi.org/10.4161/onci.19549; PMID: 22737606
   PubMed Web of Science ®Google Scholar
• Linehan DC, Tan MC, Strasberg SM, Drebin JA, Hawkins WG, Picus J, Myerson RJ, Malyapa RS, Hull M, Trinkaus K, et al. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Ann Surg 2008; 248:145 - 51; http://dx.doi.org/10.1097/SLA.0b013e318181e4e9; PMID: 18650621
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342:1432 - 3; http://dx.doi.org/10.1126/science.342.6165.1432; PMID: 24357284
   PubMed Web of Science ®Google Scholar
• Kroemer G, Zitvogel L. Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology 2012; 1:407 - 8; http://dx.doi.org/10.4161/onci.20074; PMID: 22754758
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Kepp O, Kroemer G. Immunogenic cell death in radiation therapy. Oncoimmunology 2013; 2:e26536; http://dx.doi.org/10.4161/onci.26536; PMID: 24404424
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006; 107:2409 - 14; http://dx.doi.org/10.1182/blood-2005-06-2399; PMID: 16304057
   PubMed Web of Science ®Google Scholar
• Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24:1169 - 77; http://dx.doi.org/10.1200/JCO.2005.03.6830; PMID: 16505437
   PubMed Web of Science ®Google Scholar
• Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, Cost M, Cheng P, Chang A, Redman B, et al. Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 2007; 67:7487 - 94; http://dx.doi.org/10.1158/0008-5472.CAN-07-0565; PMID: 17671219
   PubMed Web of Science ®Google Scholar
• Brandenburg S, Takahashi T, de la Rosa M, Janke M, Karsten G, Muzzulini T, Orinska Z, Bulfone-Paus S, Scheffold A. IL-2 induces in vivo suppression by CD4(+)CD25(+)Foxp3(+) regulatory T cells. Eur J Immunol 2008; 38:1643 - 53; http://dx.doi.org/10.1002/eji.200737791; PMID: 18493984
   PubMed Web of Science ®Google Scholar
• Camisaschi C, Filipazzi P, Tazzari M, Casati C, Beretta V, Pilla L, Patuzzo R, Maurichi A, Cova A, Maio M, et al. Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. Cancer Immunol Immunother 2013; 62:897 - 908; http://dx.doi.org/10.1007/s00262-013-1397-7; PMID: 23589107
   PubMed Web of Science ®Google Scholar
• Weiss L, Letimier FA, Carriere M, Maiella S, Donkova-Petrini V, Targat B, Benecke A, Rogge L, Levy Y. In vivo expansion of naive and activated CD4+CD25+FOXP3+ regulatory T cell populations in interleukin-2-treated HIV patients. Proc Natl Acad Sci U S A 2010; 107:10632 - 7; http://dx.doi.org/10.1073/pnas.1000027107; PMID: 20498045
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L, et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323 - 43; http://dx.doi.org/10.4161/onci.22009; PMID: 23243596
   PubMed Web of Science ®Google Scholar